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Early health technology assessment of
magnetic resonance-guided high intensity
focused ultrasound ablation for the
treatment of early-stage breast cancer
Floortje M. Knuttel1*†, Sèvrin E. M. Huijsse2†, Talitha L. Feenstra3, Chrit T. W. Moonen4,
Maurice A. A. J. van den Bosch1, Erik Buskens3, Marcel J. W. Greuter2 and Geertruida H. de Bock3
Abstract
Background: Magnetic resonance-guided high intensity focused ultrasound (MR-HIFU) ablation is in development
for minimally invasive treatment of breast cancer. Cost-effectiveness has not been assessed yet. An early health technology
assessment was performed to estimate costs of MR-HIFU ablation, compared to breast conserving treatment (BCT).
Methods: An MR-HIFU treatment model using the dedicated MR-HIFU breast system (Sonalleve, Philips Healthcare) was
developed. Input parameters (treatment steps and duration) were based on the analysis of questionnaire data from an
expert panel. MR-HIFU experts assessed face validity of the model. Data collected by questionnaires were compared to
published data of an MR-HIFU breast feasibility study. Treatment costs for tumours of 1 to 3 cm were calculated.
Results: The model structure was considered of acceptable face validity by consulted experts, and questionnaire data
and published data were comparable. Costs of MR-HIFU ablation were higher than BCT costs. MR-HIFU best-case scenario
costs exceeded BCT costs with approximately €1000. Cooling times and breathing correction contributed most
to treatment costs.
Conclusions: MR-HIFU ablation is currently not a cost-effective alternative for BCT. MR-HIFU experience is limited, increasing
uncertainty of estimations. The potential for cost-effectiveness increases if future research reduces treatment durations
and might substantiate equal or improved results.
Keywords: Breast cancer, MR-HIFU, HTA, Cost-effectiveness, Breast-conserving therapy
Background
Breast cancer is the most common malignancy in
women worldwide and its incidence is increasing [1, 2].
As a result of national screening programmes, most
breast cancers are detected at an early stage [3]. Early
stage breast cancer is usually treated with breast
conserving therapy (BCT), which consists of lumpec-
tomy combined with radiotherapy, followed by systemic
therapy in patients deemed at high risk of metastases
[4]. The overall prognosis after BCT is good, i.e. survival
is similar to more radical mastectomy [5]. However, any
surgical treatment always bears a risk of impaired
cosmetic results and complications [6–8].
Currently, a shift towards non-surgical and less invasive
treatment has been observed in several clinical trials,
assessing the feasibility and efficacy of minimally invasive
therapies [9–12]. One of these novel treatments is
Magnetic Resonance guided High Intensity Focused Ultra-
sound ablation (MR-HIFU) [13]. Using focused ultrasound
beams with a high power MRI-integrated HIFU systems
heat breast tumours to high temperatures, inducing co-
agulation necrosis. Possible advantages of MR-HIFU abla-
tion are a lower risk of complications such as infection
and haemorrhage, improved cosmetic outcome and the
possibility to offer the treatment in an outpatient setting
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without general anaesthesia. MRI-guidance is used for
tumour visualization and temperature measurement
during the procedures [13–15]. Initial clinical MR-HIFU
studies report the treatment of approximately 122 malig-
nant breast tumours, of which 77 were excised afterwards
to assess histopathological response. The percentage of
complete tumour ablation in these small feasibility studies
varies from 16.7 to 90% [16–25].
Besides effectiveness, potential cost-effectiveness is a
relevant aspect of introducing a new technique. MR-HIFU
ablation will only have the potential to become a primary
treatment in the future if its cost-effectiveness is accep-
table compared to surgical treatment. Because its costs
have not been assessed yet, the purpose of the current
study was early health technology assessment. While
assuming equal effectiveness of MR-HIFU and BCT, costs
for treatment using MR-HIFU ablation compared to BCT
were estimated. Additionally, the influence of several
treatment-related features on these costs was assessed.
Methods
A decision tree model was developed to evaluate the
additional costs of MR-HIFU ablation as a replacement of
BCT for the treatment of early-stage breast cancer and to
what extent these costs are influenced by several treat-
ment-related features. Equal effectiveness of MR-
HIFU ablation and BCT was assumed for these ana-
lyses, because of the limited amount of clinical data
of MR-HIFU treatments [26, 27]. Model input data
were collected in a systematic way. Where possible,
parameter estimates were based on literature. For
parameters that were not available in literature, a
survey among experts was performed. MR-HIFU ex-
perts were asked to assess the validity of the model.
In addition, the model input was validated by com-
parison of treatment duration estimates to a recent
publication on the feasibility and safety of MR-HIFU
ablation [28].
BCT and MR-HIFU scenarios
BCT was compared with MR-HIFU ablation. For BCT,
treatment consisted of surgery with sentinel lymph node
procedure, hospital admission, histopathological examin-
ation of excision specimen and adjuvant treatment in
most cases. MR-HIFU treatment comprised a pre-
treatment MRI scan, separate pre-treatment sentinel
lymph node procedure, MR-HIFU ablation in day care
setting and adjuvant treatment in most cases. Follow-up
was not taken into account in this early health technology
assessment (HTA).
Patients
MR-HIFU ablation was considered most suitable for pa-
tients with early stage breast cancer with a maximum
diameter of three centimetres with no malignant foci at
a larger distance than 1 cm from the tumour edge [29].
Additional exclusion criteria for MR-HIFU ablation
were: ductal carcinoma in situ (DCIS) and lobular histo-
logical type, as both increased the risk of incomplete
resection and ablation [30, 31], the presence of axillary
lymph node metastases and all contra-indications for
MRI. Furthermore, patients could be excluded from
MR-HIFU treatment due to the following factors
assessed on pre-treatment MRI: tumour not reachable
for the ultrasound beam, or distance from tumour to
skin or pectoral muscle < 1 cm [28].
Model
A model comprising the MR-HIFU treatment as per-
formed with the dedicated MR-HIFU breast system
(Sonalleve-based prototype, Philips Healthcare, Vantaa,
Finland) was developed [32]. The model distinguished
four separate phases: patient positioning on the MR-HIFU
system, test phase (establishment of the exact treatment
focus and treatment planning), therapeutic phase (the ac-
tual tumour ablation) and post-treatment phase (Fig. 1).
In the positioning phase, the patient was positioned on
the HIFU table, which was then placed in the MR scanner,
and tumour reachability for the HIFU beams was checked.
Next, sedation analgesia was administered and target def-
inition was performed based on MR images. In the test
phase the respiratory breathing pattern was tracked to
correct for breathing artefacts during proton resonance
frequency shift (PRFS) thermometry [15]. Additionally, in
the test phase the exact location of the focal point was
checked and adjusted if necessary. In the therapeutic
phase sonications with a higher power than used in the
test phase were applied. Using PRFS thermometry maps,
the temperature rise in the targeted tissue was followed to
ensure that ablative temperatures were reached. Test soni-
cations were applied again after switching to the next
treatment slice. In the post-treatment phase contrast-
Fig. 1 Overview of the four phases of MR-HIFU treatment
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enhanced MRI was performed to evaluate treatment
results and sedation analgesia was ceased. The patient was
admitted to a clinical ward for observation during the next
four hours. Modelling was performed in MATLAB
(R2014a). The conceptual model was tested for face
validity with MR-HIFU experts involved in the MR-HIFU
ablation feasibility and safety study performed with the
aforementioned HIFU breast system [28].
Model input data
For an overview of the model input parameters, see Table 1
and Table 2. To estimate the yearly number of early stage
breast cancer (stage I and stage II tumours (≤3 cm in
diameter)) patients, data from the Netherlands Compre-
hensive Cancer Organisation were used [33]. Several
parameters concerned duration of treatment steps and
probability of events related to treatment, e.g. reposi-
tioning a patient. These were based on a questionnaire
filled in a by a team of (inter) national experts (physicians
involved in breast cancer treatment, physicists, technicians
and physicians with MR-HIFU experience). Durations
were estimated by seven experts, probabilities by four of
those seven experts.
To estimate the time that was needed for MR-HIFU
treatment, a simplified tumour model was assumed with
sphere-shaped tumours with a diameter of 1, 2 or 3 cm.
A safety margin of 0.5 cm was added to the tumour size,
resulting in spheres with a diameter of 2, 3 or 4 cm. The
treatment cells of the HIFU device were considered
cylindrically shaped with a diameter of 3, 6, 9 or 12 mm
in the coronal plane and a height of 2, 4, 6 or 8 in the
sagittal plane respectively. These are the approximate
values provided by the dedicated MR-HIFU system [28, 32].
The number of sonications required for tumours of
different diameters was approximated by assuming
cylindrical shaped treatment cells covering a sphere
shaped tumour. The number of sonications varied with
the height and diameter of treatment cells, as follows:
treatment cells with a diameter of 9 mm and height of
6 mm resulted in 17 sonications for tumours of 1 cm, 50
sonications for tumours of 2 cm and 110 sonications for
tumours of 3 cm. Treatment cells with a diameter of
12 mm and height of 8 mm resulted in 9, 25, and 50 soni-
cations respectively.
Cost data
The average costs of BCT of the aforementioned patient
population were based on a database comprising 1,345
breast cancer patients [34]. Hereby a weighting to the
amount of women undergoing lumpectomy with or
without adjuvant therapy, i.e. systemic therapy (hormo-
nal therapy and chemotherapy) and radiotherapy, was
done [35–37]. To estimate the costs for using the MR
scanner and HIFU device, tariffs for MR procedures that
were comparable in complexity, such as brain and heart
MR imaging were used as a proxy [38]. Costs for the
sentinel node procedure and contrast enhanced MRI
were based on their tariffs [39]. Depreciation and
Table 1 Duration of treatment steps and probability of events for clinically applied MR-HIFU breast cancer treatments as predicted
by experts compared to data from the MR-HIFU feasibility study
Treatment
phase
Parameter Experts Faesibility study [28]
Unit Median Min Max Median
Positioning Time patient verification min 15 10 25 11.5
Time verification reachability min 15 7 20 14.5
Time target definition min 8 5 15 n/a
Chance of repositioning - 0.30 0.10 0.75 n/a
Test Time to place navigator min 2 1 10 1
Time MRI scan min 2.5 1 15 2.5
Time for treatment planning min 2 1 5 n/a
Time to fill LUT min 2.75 0 5 n/a
Test sonication and check focal point min 3 1 5 4
Chance of adjustment focal point per coronal plane - 0.55 0.20 0.90 n/a
Therapeutic Time therapeutic phase min 0.50 0.25 0.75 n/a
Cooling time after each sonication min 3.5 1 10 n/a
Chance of abortion per coronal plane - 0,10 0,05 0,20 n/a
Chance of resonication per coronal plane - 0.20 0.10 0.30 n/a
Post-treatment Time clinical ward min 240 120 300 n/a
Chance of complications - 0.015 0.01 0.03 n/a
n/a not available
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maintenance costs of devices were incorporated in these
tariffs. Costs of the additional MR-HIFU treatment com-
ponents, e.g. sedation costs, were based on hospital
specific rates. Costs of personnel present during the
procedures was based on estimates of time needed
multiplied by hourly costs, based on the guidance of the
National Health Care Institute (Dutch: Zorginstituut
Nederland) [40]. Costs of follow-up were not taken into
account. Costs were indexed to 2014 by using consumer
price index numbers [41].
Analysis
The costs of MR-HIFU ablation were based on the MR-
HIFU submodel. The lowest and median estimates of
time needed obtained with expert questionnaires were
used to calculate the most optimistic (‘best case’) and
less optimistic (‘median case’) MR-HIFU treatment
scenarios. MR-HIFU treatment costs for tumour sizes of
1, 2 and 3 cm were calculated. This was done for treat-
ment cells of 9 × 6 mm and 12 × 8 mm. These costs
were compared to the average BCT costs. Tornado
diagrams were constructed to describe the sensitivity of
costs to parameter estimates.
Results
Patients
Taking all possible exclusion criteria for MR-HIFU treat-
ment into account, the proportion of patients eligible for
MR-HIFU treatment was 11.9% of all patients diagnosed
with breast cancer (Table 3) [31, 42–52].
Table 2 Resource items for diagnosis and treatment unit prices for the Netherlands, and sources
Cost category Unit Price Source
Diagnostics
Pathology and evaluation € 83 Flobbe et al (2004)
DBC sentinel node procedure € 367.71 Passantenprijslijst UMC Utrecht - Overige
zorgproducten, 2014
Treatment items
Estimated costs for using MR scanner and
HIFU device
€ 11/min Overzicht tarieven onderlinge dienstverlening UMCG; 2016
Anesthetics costs € 2.44 /min Division of Vital Functions, UMC Utrecht, 2015
Costs clininal ward € 0.44/min CVZ, Handleiding voor kostenonderzoek, 2010;
Costs technician € 0.42/min CVZ, Handleiding voor kostenonderzoek, 2010; CAO universitair
medische centra 2015–2017
Costs nurse € 0.42/min CVZ, Handleiding voor kostenonderzoek, 2010; CAO universitair
medische centra 2015–2017
Costs radiologist € 1.33/min CVZ, Handleiding voor kostenonderzoek, 2010; CAO universitair
medische centra 2015–2017
DBC DCE MRI € 331 Dutch Healthcare Authority (NZA) 2012
Breast conserving therapy € 1109 https://www.zorginstituutnederland.nl/
Radiation therapy € 3179 Flobbe et al (2004); LPRM and NABON (2000);
Slotman et al (2000)
Chemo therapy € 1044 Flobbe et al (2004); Slotman et al (2000)
Hormonal therapy € 806 Flobbe et al (2004); Slotman et al (2000)
Specialist Visits € 738 Flobbe et al (2004);
Specialist visits (adjuvant therapy) € 1966 Flobbe et al (2004);
Hospital stay € 1753 Flobbe et al (2004); Oostenbrink et al (2000)
Table 3 Proportion of patient eligible for MR-HIFU treatment
Inclusion criteria Proportion (%)
Tumour≤ 3 cm 78.6
No lymph node metastasis 65.0
No lobular subtype 90.2
No EIC 84.6
No previous surgery 91.3
No renal insufficiency 97.3
Not multifocal 82.0
No BRCA mutation 97.4
Tumour reachable 66.3
Distance to skin≥ 1 cm 65.0
Eligible patientsa 11.9
EIC extensive intraductal component
ai.e. all of the inclusion criteria present
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Model
The structure of the model was considered of acceptable
face validity by experts consulted. Model input parameters
on analogous variables derived from actually observed
data were comparable to the answers obtained through
the questionnaires [28]. The duration and chances of
occurrence of the different MR-HIFU treatment steps,
compared to the data observed in the feasibility study, is
shown in Table 1.
Costs of MR-HIFU ablation and BCT
The costs of MR-HIFU ablation for best and median
case scenarios and two different cell sizes and the costs
of BCT for tumours of 1, 2 or 3 cm are displayed in
Table 4. The larger the treatment cell, the lower the
MR-HIFU costs and the shorter the procedure time. For
all variants, the costs of MR-HIFU ablation were higher
than the costs of BCT. When using treatment cells size
of 12 × 8 mm, the best case scenario costs of MR-HIFU
ablation approached those of BCT.
Factors influencing treatment costs
Factors contributing most to the total treatment costs
were: cooling time after each sonication, and time
required for breathing correction. For 9 × 6 mm treat-
ment cells the average sensitivity for cooling time over
all tumour sizes was 64.6 ± 10.3%, for the breathing cor-
rection this was 28 ± 2.7%. For treatment cells of 12 ×
8 mm this was 59.3 ± 10.8% and 29.1 ± 1.6% respectively.
Changes in these two parameters had larger impact on
the cost estimations of treatments with smaller treat-
ment cells than with larger treatment cells. The
Table 4 Costs of MR-HIFU ablation for best and median case scenarios compared to costs of BCT
MR-HIFU ablation BCT
Median case Best case
Treatment cell size (mm) Treatment cell size (mm)
6 × 9 12 × 8 6 × 9 12 × 8
Tumour size (mm) Costs (€1000) Time (h) Costs (€1000) Time (h) Costs (€1000) Time (h) Costs (€1000) Time (h) Costs (€1000)
10 11.5 4.4 10.0 2.8 8.5 1.1 8.2 0.8 7.1
20 15.5 8.8 12.5 5.4 9.1 1.9 8.6 1.3 8.1
30 23.3 17.4 15.5 8.8 10.5 3.4 9.1 1.9 8.1
Table 5 Variance (%) of uncertainties in tornado diagrams. A safety margin of 0.5 cm is added to the tumour size
Treatment
phase
Tumour size (mm)a 10 20 30
Treatment cell size (mm) 9×6 12×8 9×6 12×8 9×6 12×8 9×6 12×8
Parameter Mean sd Mean sd
Positioning Time patient positioning 0.5 1.6 0.1 0.3 0.0 0.1 0.2 0.3 0.7 0.8
Time verification reachability 0.4 1.2 0.1 0.2 0.0 0.1 0.2 0.2 0.5 0.6
Time target definition 0.1 0.4 0.0 0.1 0.0 0.0 0.0 0.1 0.2 0.2
Chance of repositioning 0.5 1.6 0.1 0.3 0.0 0.1 0.2 0.3 0.7 0.8
Test Time MR scan 7.7 8.9 1.2 4.1 0.5 1.2 3.1 4.0 4.7 3.9
Time to place navigator 3.2 3.7 0.5 1.7 0.2 0.5 1.3 1.7 2.0 1.6
Time to perform treatment planning per
coronal plane
0.6 0.7 0.1 0.3 0.0 0.1 0.2 0.3 0.4 0.3
Time to fill LUT 31.0 30.2 27.2 29.8 25.9 27.2 28.0 2.7 29.1 1.6
Time to perform test sonications and
verify focal point
1.5 1.7 0.2 0.8 0.1 0.2 0.6 0.8 0.9 0.8
Chance of readjustment focal point 0.6 0.7 0.1 0.3 0.0 0.1 0.2 0.3 0.4 0.3
Therapeutic Time to perform therapeutic sonication 0.2 0.1 0.2 0.2 0.2 0.2 0.2 0.0 0.2 0.1
Cooling time after each sonication 52.8 47.8 69.2 60.9 71.8 69.2 64.6 10.3 59.3 10.8
Chance of resonication per coronal plane 0.8 0.7 1.1 1.0 1.1 1.1 1.0 0.2 0.9 0.2
Post treatment Time clinical ward 0.2 0.5 0.0 0.1 0.0 0.0 0.1 0.1 0.2 0.3
Sensitivity (variance) was calculated by calculation of the swing square relatively to the total swing square. Hereby, the swing is the range of cost values for a
given uncertainty
aA safety margin of 0.5 cm was added to the tumour size
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sensitivity of each model input parameter on model out-
put is shown in Table 5 in tornado diagrams. The sensi-
tivity values for both 9 × 6 mm and 12 × 8 mm
treatment cells are presented in respectively Fig. 2 and 3.
Discussion
To our knowledge, this is the first study on the potential
cost-effectiveness of MR-HIFU ablation of breast cancer.
This early health technology assessment suggests that
MR-HIFU ablation was more expensive than BCT.
When larger treatment cells were assumed, the potential
for MR-HIFU ablation to have comparable costs
increased. The duration of certain treatment steps
including cooling time after each sonication and the
time needed to apply breathing correction, had most
impact on MR-HIFU costs. Importantly, the analyses
were performed under the assumption that MR-HIFU
ablation and BCT are equally effective.
Due to the limited amount of MR-HIFU treatment
data, the clinical effectiveness, complication rate and
the effect on quality of life and cosmetic outcome is
still scarce. Therefore, the effectiveness of MR-HIFU
ablation was considered equal to BCT and complica-
tions were not taken into account. However, if MR-
HIFU treatment would be optimized and surgical
excision would be omitted in the future, surgical
complications and breast deformation might occur
less frequently. This is expected to have a favourable
effect on quality of life and cosmetic outcome. Even
if MR-HIFU ablation would be slightly less effective
than BCT, some patients might still prefer MR-HIFU
because of its favourable effect on cosmetic outcome
Fig. 2 Tornado diagrams presenting sensitivity to parameter values of the difference in treatment costs for tumours of 10, 20 and 30 mm with an
added safety margin of 5 mm assuming treatment cells of 9 × 6 mm
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or reduced risk of complications. Especially elderly
patients with more comorbidities and shorter life
expectancy may be interested in MR-HIFU ablation.
Quality of life measures are usually incorporated in
cost-effectiveness analyses as well, and hence better
treatment associated utility scores would increase the
potential for MR-HIFU to become cost-effective [53].
Our results indicate that in order to improve the cost-
effectiveness of MR-HIFU ablation treatment time
should be reduced. The currently used cooling times are
applied to guarantee safety. If more clinical experience
with MR-HIFU ablation is gained, shorter cooling times
may possibly appear equally safe. Being able to measure
the temperature in the surrounding (adipose) tissue in
the breast may contribute by providing real time
temperature measurements during cooling. Possible
methods for thermometry in adipose tissue are T2-
weighted thermometry [54, 55] or a hybrid method for
thermometry in fat and adipose tissue at the same time
[56, 57]. Implementation of these techniques will
Fig. 3 Tornado diagrams presenting sensitivity to parameter values of the difference in treatment costs for tumours of 10, 20 and 30 mm with an
added safety margin of 5 mm assuming treatment cells of 12 × 8 mm
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become possible in the near future. The time needed for
breathing correction could be improved by using sed-
ation that results in a more regular breathing pattern, or
even obviates the need for breathing correction. Further-
more, the parameters of breathing correction could be
made more flexible enabling sonications to start after a
shorter period. To what extent this is possible should be
clinically investigated first and is not expected in the
near future. Another reason for the higher costs of
MR-HIFU ablation is the separately performed senti-
nel lymph node procedure, which is incorporated in
the operation for BCT.
Strong points of this study are that it provided the first
data on the potential cost-effectiveness of MR-HIFU
ablation and that MR-HIFU experts validated the applied
treatment models. Due to the lack of empirical treat-
ment data, other sources for model input were needed.
Estimations of experts are the most accurate option in
this case. Furthermore, the duration of several treatment
elements was validated with the published MR-HIFU
breast study in which the dedicated MR-HIFU breast
system was used [28].
Some limitations of the present study should also be ac-
knowledged. First, MR-HIFU treatment duration may
have been overestimated as a result of the lack of experi-
ence. As mentioned before, cooling times may be un-
necessarily prolonged. Besides, no experience with total
tumour ablation exists yet, possibly affecting some
estimations. Second, treatment cells were assumed to be
cylindrical shaped to enable calculations of the number of
sonications required per tumour. The MR- HIFU breast
system provides treatment cells with the shape of an ob-
late ellipse. This difference in shape may have affected the
results. Third, the costs of BCT may have been overesti-
mated, as this cost estimate also comprised patients with
lobular carcinoma and positive axillary lymph nodes.
However, patients with a tumour of the lobular subtype
are considered ineligible for MR-HIFU treatment, as lobu-
lar breast cancer has a higher risk of incomplete resection
and is consequently more expensive to treat. The same ap-
plies for patients with positive axillary lymph nodes.
Fourth, our estimations were based on the dedicated MR-
HIFU breast system used in our centre (Sonalleve-based
prototype, Philips Healthcare, Vantaa, Finland). Other
MR-HIFU systems exist and it is unclear if our results
would be generalizable to these systems. Fifth, the cost
data is based on the local health system. This means that
the cost data cannot be extrapolated to other countries.
However, we have generated a model that is usable inter-
nationally. Lastly, in the performed early HTA indirect
costs were not taken into account. For example, the ex-
pected duration of absence at work will be longer after
breast surgery than after MR-HIFU. As a result, the costs
of BCT may have been underestimated in this study.
Several issues need to be addressed before MR-HIFU
ablation can become a clinical treatment. First of all, the
clinical efficacy of MR-HIFU has to be proven. MR-HIFU
is competing with a very reliable and well-established
treatment option, BCT. Clinical trials on MR-HIFU are
therefore hard to perform and require many participants.
Other concerns are that no surgical excision specimen is
available after MR-HIFU treatment, the indication for
adjuvant treatment needs to be assessed prior to treat-
ment. Furthermore, margin status cannot be assessed,
which may be resolved by frequent follow-up with MRI.
In conclusion, MR-HFIU ablation is a novel treatment
which is currently not ready for clinical implementation,
but recent developments are promising for the future.
Conclusions
We tentatively conclude that MR-HIFU ablation currently
is not a cost-effective alternative to BCT. The costs of
MR-HIFU ablation are mostly affected by the long
duration of certain treatment components, i.e. cooling
time after sonications and the time needed to apply
breathing correction. Furthermore, costs were influenced
by the size of treatment cell used and decreased with
larger treatment cell size. Being an early HTA analysis, the
study had to be based on several assumptions and estima-
tions, because the experience of MR-HIFU ablation is still
quite limited. Therefore, our results may give important
directions for future development of MR-HIFU ablation.
Especially cooling time in between sonications and accu-
rate breathing correction take relatively long and thus
appear relevant targets for further innovation.
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